SCHEMBL3248704

SCHEMBL3248704

CON(OC)C(Cc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
SRR Q9GZT4 2/20 0.47
ALPI P09923 1/20 0.47
PKM P14618 1/20 0.47
PTGS1 P23219 1/20 0.47
XIAP P98170 1/20 0.47
SLC7A5 Q01650 1/20 0.47
LAP3 P28838 1/20 0.46
MAPT P10636 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ADAMTS5 Q9UNA0 1/20 0.45
CPA1 P15085 2/20 0.44
CPA3 P15088 2/20 0.44
FOLH1 Q04609 1/20 0.44
CPB1 P15086 1/20 0.44
CPB2 Q96IY4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472008 1.00 CYP1A2 (0.50) CYP1A2PPARGPPARASRRALPI
SCHEMBL27516881 0.86 ATM (0.49) MAPTALDH1A1MEN1POLBCYP2C9
SCHEMBL6694352 0.86 ACE (0.42) MEN1KMT2ANPC1RAB9A
Tyrosine SCHEMBL2672368 0.85 SLC7A5 (0.61) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL7452871 0.83 CYP1A2 (0.47) CYP1A2SRRALPIPKMPTGS1
SCHEMBL7452874 0.83 CYP1A2 (0.47) CYP1A2SRRALPIPKMPTGS1
SCHEMBL7424670 0.81 CYP1A2 (0.46) CYP1A2PPARGPPARASRRALPI
SCHEMBL7424666 0.81 CYP1A2 (0.46) CYP1A2PPARGPPARASRRALPI
Hydrochloric Acid SCHEMBL11438414 0.81 ALPI (0.47) CYP1A2PPARGPPARASRRALPI
SCHEMBL7552899 0.80 SRR (0.46) CYP1A2PPARGPPARASRRALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3991077-A SOLVENT AJINOMOTO CO., INC. (JA) 1976-11-09 US claimed
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof GENEFRONTIER CORPORATION (JP) 2026-03-03 US disclosed
WO-2025111511-A2 REVERSIBLY REACTIVE AFFINITY SELECTION MASS SPECTROMETRY AND USES THEREOF CALICO LIFE SCIENCES LLC (US) 2025-05-30 WO disclosed
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF GENEFRONTIER CORPORATION (JP) 2024-03-21 US disclosed
CN-108047304-A - 7 selective depressant of metalloproteinases and its preparation method and application 延边大学 2018-05-18 CN disclosed
EP-3247697-A1 PROCESS AND INTERMEDIATES FOR THE RACEMIZATION OF ENANTIOMERICALLY ENRICHED 1-AMINOINDANE Farma GRS, d.o.o. (SI) 2017-11-29 EP disclosed
CN-107012179-A The enzymatic conversion preparation method of 3,4 dimethoxy L phenylalanines 南京医科大学 2017-08-04 CN disclosed
CN-106999536-A Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions 百时美施贵宝公司 2017-08-01 CN disclosed
EP-3068746-A1 PROCESS FOR THE PREPARATION OF ENATIOMERICALLY PURE 1-AMINOINDAN Farma GRS, d.o.o. (SI) 2016-09-21 EP disclosed
WO-2016116607-A1 PROCESS AND INTERMEDIATES FOR THE RACEMIZATION OF ENANTIOMERICALLY ENRICHED 1-AMINOINDANE FARMA GRS D.O.O. (SI) 2016-07-28 WO disclosed
US-20050026840-A1 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics CUREGENICS LTD. (IL) 2005-02-03 US disclosed
WO-2004110337-A2 CELL PERMEABLE CONJUGATES OF PEPTIDES FOR INHIBITION OF PROTEIN KINASES DEVELOGEN ISRAEL LTD. (IL) 2004-12-23 WO disclosed
EP-1416934-A2 PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS Peptor Ltd. (IL) 2004-05-12 EP disclosed
WO-2003010281-A2 PROTEIN KINASE INHIBITORS COMPRISING ATP MIMETICS CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS PEPTOR LTD. (IL) 2003-02-06 WO disclosed
WO-2002048312-A2 BACKBONE CYCLIZED INHIBITORS OF HEAT SHOCK PROTEINS PEPTOR LTD. (IL) 2002-06-20 WO disclosed
EP-0644772-A4 OPIOID PEPTIDES. BIOMEASURE INC (US) 1997-01-29 EP disclosed
EP-0644772-A1 OPIOID PEPTIDES BIOMEASURE, INC. (US) 1995-03-29 EP disclosed
WO-1994011018-A1 OPIOID PEPTIDES BIOMEASURE, INC. (US) 1994-05-26 WO disclosed
EP-0351382-A2 Process for the synthesis of optically active aminoacids MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1990-01-17 EP disclosed
EP-0000745-B1 SALT OF AN OPTICALLY ACTIVE ISOMER OF PHENYLGLYCINE AND AN OPTICALLY ACTIVE ISOMER OF 2-AMINO BUTANOL AND PROCESS FOR ITS PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1981-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF CXCL10, CXCR3, CXCR6 CYP1A2 4822/4885PPARG 4740/4885PPARA 4709/4885
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof CXCL10, MLX, MICA CYP1A2 4798/4885PPARG 4347/4885PPARA 4357/4885
US-20050026840-A1 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics PRKCQ, ADK, PRKCH CYP1A2 4860/4885PPARG 3339/4885PPARA 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.